oportuzumab monatox
conatumumab
anti-nuclear factor
antinucleotide
zanolimumab
alacizumab
microantibody
immunogen
heterophile
atezolizumab
immunoaffinity
antisynthetase
heterophilic
affitin
pozelimab
sasanlimab
sintilimab
dinutuximab
toripalimab
immunoadaptor
countercorrelated
vanucizumab
retifanlimab
polyvalent
paratope
guselkumab
ziltivekimab
antigenomic
phosphospecific
solitomab
zenocutuzumab
properdin
glembatumumab
radioimmunoelectrophoresis
immunoaccessible
immunoblotting
immunoprotein
intetumumab
patritumab
bursopentine
siltuximab
inotuzumab
duligotuzumab
-ab
robatumumab
oleclumab
immunocytology
immunodepleted
affibody